Program On Regulation, Therapeutics, And Law
@PORTAL_Research
Followers
3K
Following
4K
Media
993
Statuses
5K
Division of Pharmacoepidemiology, @BrighamWomens @HarvardMed • Director @akesselheim RETHINKING MEDICATIONS by Dr. Jerry Avorn - Out Now! https://t.co/28nmi4UeA1
Boston, Massachusetts
Joined October 2014
0
0
0
RT @AdamR_PhD: Excited to get this brand new book by Jerry Avorn from @PORTAL_Research in the mail today! Can't wait to give it a read! . @….
0
2
0
Out now from Dr. Jerry Avorn— RETHINKING MEDICATIONS: Truth, Power, and the Drugs You Take. In his new book, Dr. Avorn explains why some medications are poorly evaluated, overpriced, or pose unwarranted risks—and how we fix that. Grab a copy today:
1
1
2
View his full testimony before the Health Subcommittee: Read his written testimony:
0
0
1
And, on strategies to improve the biosimilar market, including by implementing policies to facilitate biosimilar interchangeability, clear patent thickets, and preventing biosimilar rebate gaming by PBMs.
1
2
4
On protecting Medicaid - “Cutbacks planned for the Medicaid program will force states to severely limit their drug coverage, which will inevitably lead to patient deaths.”
1
0
1
WATCH: @akesselheim's testimony yesterday before @WaysMeansCmte. On NIH cuts - ". the next generation will look back at this moment & ask what we were doing while the Trump administration systematically disposed of 1000s of research projects that could've helped patients."
1
2
6
RT @Arnold_Ventures: Happening now: @WaysandMeansGOP hearing on lowering costs for patients: The health of the biosimilar market featuring….
0
1
0
Tune in TODAY at 10am ET as PORTAL Director Aaron Kesselheim testifies before the House Ways & Means Health Subcommittee: He'll be discussing threats to US biomedical research, the need to protect and expand Medicare drug price negotiation, and more.
0
0
1
RT @wbfeldman: I'm excited to share a new study out today @bmj_latest comparing the two single-inhaler triple therapies on the US market.….
0
6
0
RT @oncology_bg: Published today in @JAMAOnc with @akesselheim and @PORTAL_Research team. We discuss the case of cancer drug Xtandi whose….
0
5
0
RT @AdamR_PhD: Presenting some work on QALY-based cost-effectiveness analyses at #SMDM24 that shows some arguments against the use of QALYs….
0
5
0
RT @DrHussainL: 💊 New study in JAMA provides clear steps busy clinicians & staff can take to help patients struggling to afford their presc….
0
23
0
Interested in the strategies and tools clinicians can use to help their patients afford prescription drugs? . Check out this new overview in @JAMA by @DrHussainL, Catherine Hwang, @bnrome, and @akesselheim highlighting the options available to patients.
This article describes strategies that clinical teams can use to help patients afford prescription drugs and proposes an algorithm to help identify which strategies may be most helpful based on insurance status and type of drug.
0
3
6
RT @NEJM: The federal government has proven that it can navigate the difficult process of identifying drugs for price negotiation, gatherin….
0
3
0
RT @NEJM: In order to ensure timely testing of drugs that have been granted accelerated approval, the FDA can impose civil monetary penalti….
0
10
0
RT @JAMA_current: Despite the Pediatric Research Equity Act, which applied to only 30% of new drugs approved 2015-2021, >50% of required po….
0
2
0
RT @wbfeldman: New piece out led by Jelle Stoelinga examining supplemental indications on oncology drugs in the US vs EU. .
0
2
0
RT @Eddie_Cliff: Just out @NEJM, @DavalJoseph @akesselheim & I discuss strategies to reduce already-delayed confirmatory trials for acceler….
0
24
0
RT @HMSbioethics: NOVEMBER 15: join us for 'Improving Im/migrant Health Care Access: Moving In the Right Direction?' with @PORTAL_Research….
0
2
0